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1 Introduction
1.1 Angiotensin receptors as possible therapeutic targets in treatment of mood
disorders
Renin-angiotensin-aldosterone system (RAAS) is one of the body’s regulator systems that are
dedicated to maintaining homeostasis. Main functions of the RAAS are the regulation of the liquid
homeostasis and blood pressure. RAAS forms a feedback system where the first released hormone
triggers secretion of other hormones, which finally leads to a physiological response that when
registered, down-regulates the activity of the whole system. Renin is the first product of the RAAS
and it induces the conversion of circulating angiotensinogen into angiotensin I. Following this,
angiotensin-converting enzyme (ACE) converts angiotensin I into the active form of angiotensin,
angiotensin II (ANG). This final product is responsible for many of the physiological effects of
RAAS, such as aldosterone secretion and vasoconstriction that lead to the elevation in blood
pressure.
ANG receptor type 1 (AGTR1) and ANG receptor type 2 (AGTR2) are the main targets of
ANG that are expressed both in the periphery and the central nervous system (CNS) (Guimond and
Gallo-Payet, 2012). In general, these G-protein-coupled receptors (GPCR) are expressed by
different neuronal subtypes in the brain (de Kloet et al., 2016). ANG binding to AGTR results in
different physiological outcomes that are determined by the receptor type that is activated
(Guimond and Gallo-Payet, 2012). The classical effects of ANG are achieved by the activation of
AGTR1, Gq-type and Gi-type of GPCR, that triggers several distinct signaling pathways, including
G-proteins, tyrosine kinases and mitogen-activated protein kinases (MAPK) (Hunyady and Catt,
2006). Stimulation of AGTR1 has been associated with hypertension and the development of
cardiovascular diseases by particularly triggering Janus kinase - signal transducer and activator of
transcription (JAK-STAT) signaling pathway (Hunyady and Catt, 2006).
Stress has been shown to elevate the activity of AGTR1 and induce anxious behavior
(Saavedra et al., 2006; Campos et al., 2020). Even though classically AGTR1 antagonists have been
used to treat hypertension, different AGTR1 antagonists exhibits antidepressant- (AD) and
anxiolytic-like effects, indicating that AGTR1 plays an important role modulating stress-coping
behavior (Srinivasan et al., 2003; Saavedra et al., 2006; Diniz et al., 2018; Campos et al., 2020).
Additionally, AGTR1 antagonist telmisartan successfully restored the production of brain-derived
neurotrophic factor (BDNF) that had been diminished in response to stress (Wincewicz et al., 2016),
which is a common consequence of chronic stress (Castrén, 2014). Another study demonstrated that
the therapeutic effect of AGTR1 antagonists is associated with enhanced signaling between ANG
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and AGTR2 and triggered Fyn pathway, which results in the enhanced BDNF:TRKB signaling
(Diniz et al., 2018).
Recently, AGTR1 antagonists and ACE inhibitors (ACEI) have been investigated as
candidates of compounds to increase plasticity and possibly improve neuropsychiatric conditions.
Compared to AGTR1 antagonist losartan that possesses an anxiolytic-like effect on
hypertension-induced anxiety in rats, the effect of ACEI enalapril were found to be weaker
(Srinivasan et al., 2003). Furthermore, losartan was also effective in the normotensive animals
(Srinivasan et al., 2003). Interestingly, these authors speculated that the weaker effect of enalapril
might be derived from its additional reduction of the neuroprotective function of AGTR2
(Srinivasan et al., 2003).
AGTR2 is a Gi-type of GPCR and it’s activation triggers, for instance, phosphatase
pathways, kinase pathways, and the activation of other receptors (Guimond and Gallo-Payet, 2012).
These signaling pathways include peroxisome proliferator-activated receptor gamma (PPAR-y),
MAPK phosphatase (MKP), and Src family kinase (SFK), such as Fyn (Guimond and Gallo-Payet,
2012). In contrast to AGTR1, AGTR2 stimulation is assumed to be neuroprotective (Namsolleck et
al., 2013) and AGTR2-deficiency leads to increased anxiety (Okuyama et al., 1999). Thus, as the
therapeutic effects of AGTR1 antagonists may be dependent on facilitating the interaction between
ANG:AGTR2 (Diniz et al., 2018), AGTR2 agonists, that directly enhance the function of this
receptor, might offer a novel tool to treat mood disorders.
Compound 21 (C21) is the first synthesized nonpeptide molecule that selectively targets and
activates AGTR2 (Wan et al., 2004). This AGTR2 agonist increases neuronal outgrowth (Wan et al.,
2004; Namsolleck et al., 2013), neuronal reinnervation and axonal plasticity (Namsolleck et al.,
2013). C21 has also been observed to attenuate the neuronal consequences of ischemic stroke and
myocardial infarction (McCarthy et al., 2014; Bennion et al., 2018). Additionally, C21 has been
associated with anti-inflammatory (Kaschina et al., 2008; Rompe et al., 2010) and anti-apoptotic
effects that led to improved cell survival (Kaschina et al., 2008; Namsolleck et al., 2013). C21 has
been shown to potentiate the effect of AGTR1 antagonist candesartan on the elevated blood
pressure in hypertensive rats (Bosnyak et al., 2010). However, C21 by itself seems to have no
antihypertensive properties (Bosnyak et al., 2010; Bennion et al., 2018).
The beneficial effects of C21 are prevented in the cells lacking AGTR2 or that had been
previously exposed to the AGTR2 antagonist PD123319 (Namsolleck et al., 2013). Similarly, the
neuroprotective effect of this AGTR2 agonist on stroke disappeared in the rats that were treated
with the combination of C21 and PD123319 (McCarthy et al., 2014). Together these studies
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confirm that the selective stimulation of AGTR2 is indeed an essential part of the neuroprotective
effects of this drug. Moreover, the beneficial effects of C21 seems to involve neurotrophin signaling
as the neurotrophin receptor inhibitor K252a efficiently compromises the neuronal outgrowth in the
C21-treated cells (Namsolleck et al., 2013). Interestingly, an enhanced synthesis of BDNF,
tropomyosin receptor kinases B (TRKB) and A (TRKA) was observed in the cells treated with C21
(Namsolleck et al., 2013).
1.2 The role of BDNF and TRKB signaling in AD-induced plasticity
TRKB is the high-affinity receptor of BDNF, and together these molecules participate in the
activity-dependent plasticity that allows the CNS to adapt to the constantly changing internal and
external environmental circumstances (Castrén and Antila, 2017). This process is dependent on the
activity of neuronal connections, and thus the most commonly used connections are enhanced
(Castrén and Antila, 2017). On the contrary, the connections that lose the competition to the more
active ones perish (Castrén and Antila, 2017). The activity of neuronal connections leads to the
enhanced BDNF:TRKB signaling that determines the final outcome of activity-dependent plasticity
(Castrén and Antila, 2017). Furthermore, it has been widely accepted that the therapeutic effects of
classical and atypical ADs work through a BDNF:TRKB-dependent mechanism of action (Castrén
and Antila, 2017) and elevate the activity of TRKB in the brain (Umemori et al., 2018).
Interestingly, the major depressive disorder (MDD) seems to result in the reduction of the serum
BDNF (Karege et al., 2002). Additionally, BDNF-deficient animals do not benefit from the AD
treatments (Karpova et al., 2011), which further demonstrates the crucial role of BDNF. Because of
this, compounds that are able to enhance BDNF:TRKB signaling could be used as new therapeutic
tools to treat mood disorders.
According to the network hypothesis of depression, the mood disorders are an end result of
altered signaling of the neural network that can be recovered with the AD treatment (Umemori et
al., 2018). By enhancing the BDNF:TRKB signaling, ADs are able to produce a critical period-like
state called juvenile-like plasticity (iPlasticity), where the plasticity is elevated (Castrén and Antila,
2017; Steinzeig et al., 2017; Umemori et al., 2018; Steinzeig et al., 2019). Interestingly, iPlasticity
allows the neuronal network of an adult brain to be modified more freely through
activity-dependent plasticity (Castrén and Antila, 2017, Umemori et al., 2018).
Activity-dependent plasticity and the mood recovering effect of ADs are closely related to
BDNF:TRKB signaling. For example, the BDNF synthesis and the amount of surface TRKB has
been shown to increase in response to neuronal activity (Castrén and Antila, 2017; Umemori et al.,
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2018). Furthermore, chronic AD treatments induce elevated BDNF and TRKB synthesis, whereas
the acute treatments are able to enhance TRKB activation (Castrén and Antila, 2017). Direct
manipulation of BDNF has provided an interesting standpoint to investigate its role in the AD
effect. For example, chronic infusion of BDNF into the midbrain of rats improved their
performance in the learned helplessness (LH) and forced swimming test (FST) (Siuciak et al.,
1997). Furthermore, an acute infusion of BDNF into the hippocampus (HC) of rats induced a
long-lasting antidepressant-like effect (Shirayama et al., 2002). Our recently published study has
also shown that AD-induced plasticity and other therapeutic effects of different ADs are induced by
the direct interaction between ADs and a specific motif of TRKB transmembrane domain
(Casarotto et al., 2021).
Since ADs allow the reinstatement of plasticity, the best outcome of treating mood disorders
is achieved when the reshaping of neuronal networks is guided by a proper activity such as
psychotherapy (Castrén and Antila, 2017; Umemori et al., 2018). In fact, there is already evidence
supporting this finding, whereas the ADs and psychotherapy on their own have turned out to be less
effective (Pampallona et al., 2004; Umemori et al, 2018). Furthermore, the AD fluoxetine reduces
the consequences of contextual fear conditioning when the fear memories are reshaped by
extinction training (Karpova et al., 2011). However, the combined effects of these treatments seem
to be necessary for the observed therapeutic effects as they disappear in mice that only received
fluoxetine without extinction training or vice versa (Karpova et al., 2011). Interestingly, the
combined treatment was not able to attenuate fear in BDNF-deficient animals (Karpova et al.,
2011), and similarly the antidepressant-like effect induced by AGTR1 antagonist losartan is
diminished in these animals (Diniz et al., 2018). In fact, the therapeutic effects of ADs disappear
when either BDNF or TRKB function has been compromised (Castrén and Antila, 2017). All in all,
it can be concluded that the BDNF:TRKB signaling plays a crucial role in the AD-induced
plasticity.
1.3 Contextual fear conditioning and anxiety
Contextual fear conditioning, also known as Pavlovian fear conditioning, is a validated method to
investigate fear and formation of fear memories (Giustino and Maren, 2015). In the contextual fear
conditioning the animals are exposed to a distinguishable but neutral context that will be associated
with a fear-inducing stimulus. When animals are returned back to the familiar context, the
environment by itself should induce fear, observed as freezing, even when the fear-inducing
stimulus is not present. The effects of ADs have also been investigated in the contextual fear
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conditioning where their therapeutic effects lead to reduced freezing and thus, relieved conditioned
fear (Burghardt and Bauer, 2013). For example, a chronic treatment of AD fluoxetine has been able
to reduce the consequences of stress in rats that were exposed to fear conditioning (Zhang et al,
2000).
Fear conditioning consists of the acquisition, consolidation and retrieval of fear memories
that can be attenuated to some extent by the extinction training where the animals are re-exposed to
the source of fear without the fear-inducing stimulus (Burghardt and Bauer, 2013). However,
extinction training by itself is not able to prevent spontaneous recovery (recovery of freezing
response with re-exposure) but when combined with AD treatment, the fear memories can be
overwritten by new, neutral experiences in the familiar context (Karpova et al., 2011).
The elevated plus-maze (EPM) is a validated ethological model to investigate anxiety and
anxiolytic-like effects of drugs (Walf and Frye, 2007), such as ADs. In comparison to contextual
fear conditioning, generally EPM does not contain any conditioning stimulus (Walf and Frye,
2007). Instead, the anxious behavior is induced in rodents by the distressing environment as the
apparatus is placed above the floor and the two of the four arms of the EPM lack surrounding,
protective walls (Walf and Frye, 2007). As a result, an approach-avoidance conflict towards the
open arms (OAs) of the EPM is established, and in general, animals show a clear preference
towards secure enclosed arms (EAs) of the apparatus (Walf and Frye, 2007). The anxiolytic effect
of ADs reflect on the animal’s behavior by increasing their interest towards approaching the OAs,
which would lead to the elevated OA activity (Walf and Frye, 2007). However, to gain a deeper
insight into the mechanisms of conditioned and unconditioned fear, it is important to understand
their relation to the brain.
Fear and formation of fear memories are regulated by several different parts of the brain that
together form an interconnected network, respectively a fear circuit (Giustino and Maren, 2015).
The main regulators of the fear circuit are the amygdala, HC and medial prefrontal cortex (mPFC),
the latter being the structure that guides the functions of the other parts of this system according to
received and previous information (Giustino and Maren, 2015). Fear conditioning leads to
alterations in the activity of the mPFC-located neurons even when the animals are exposed to the
familiar context in the absence of fear-inducing stimulus (Baeg et al., 2001). Interestingly, the
activity of these neurons is restored by extinction training (Baeg et al., 2001). Whereas mPFC
regulates the behavioral aspects of fear, the acquisition of conditioned fear is modulated by the
amygdala and HC, which crucially contributes to storing contextual information in the long-term
memory (Giustino and Maren, 2015). Furthermore, amygdala participates in the extinction of
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conditioned fear (Giustino and Maren, 2015), and in fact the beneficial effect of fluoxetine on fear
extinction is based on enhancing the activity-dependent plasticity in the amygdala (Karpova et al,
2011).
Similar to conditioned fear, the fear circuit is also involved in the regulation of anxiety and
unconditioned fear along with the bed nucleus of stria terminalis (BNST) located in the proximity
of amygdala (Calhoon and Tye, 2015). Unconditioned fear response consists of four stages,
respectively detection, identification, evaluation and finally, behavioral responses (Calhoon and
Tye, 2015). The amygdala is responsible for identifying the potential threat and inducing
unconditioned fear response whereas the other parts of the circuit further confirm if the situation is
indeed threatening (Calhoon and Tye, 2015). Compared to conditioned fear, the fear circuit works in
a rather similar manner in the unconditioned fear as the mPFC determines the final behavioral
outcome of the fear response (Calhoon and Tye, 2015).
Despite the carefully structured regulation system, even harmless environmental stimuli can
be identified as a threat in some circumstances, followed by the typical anxious behavior such as
activation of the sympathetic nervous system and fight-or-flight response (Calhoon and Tye, 2015).
Furthermore, the network signaling can be altered chronically as observed in the MDD, which has
been associated with a significant downregulation of cortical gamma-aminobutyric acid (GABA)
accompanied by an upregulation of glutamate (Sanacora et al., 2004). Since GABA and glutamate
are the major inhibitory and excitatory neurotransmitters, respectively, the alterations in their
abundance impact the whole network signaling (Sanacora et al., 2004).
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2 Hypothesis
The administration of C21 facilitates the activation of TRKB, which in turn reduces the
consequences of stress and anxiety in mice.
3 Aims of the study
This study aimed to test if the in vitro and the in vivo effects of C21 are related to the BDNF:TRKB
signaling. The in vitro effects were investigated with enzyme-linked immunosorbent assay (ELISA)
whereas contextual fear conditioning and EPM were used to address the effect of C21 in stress and
anxiety. The following questions were covered in this study:
1) Does C21 treatment elevate the amount of surface TRKB?
2) Is C21 treatment able to facilitate the effect of BDNF in vitro?
3) Does C21 protect from the stress and anxiety in vivo?
4) Are these in vivo effects of C21 dependent on BDNF?
5) What cell subtypes express AGTR2 in the brain?
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4 Material and methods
4.1 In vitro experiments
4.1.1 Drug treatments in vitro
C21 (sodium salt, MW = 497.61, purity = 97.7%) was provided by Vicore Pharma, Sweden as a
kind gift. Dimethyl sulfoxide (DMSO) was used as a vehicle for C21 (ctrl; 0.1; 1.0; 10μM).
Respectively, phosphate-buffered saline (PBS) was used as a vehicle for recombinant human BDNF
(Peprotech, #450-02, 0.1 ng/ml).
4.1.2 Cortical cell cultures, drug treatment and sample collection
The rat cortical cell cultures were used in all in vitro experiments. All cell cultures were kindly
prepared for this project by lab technicians of the Neuroscience Center, using embryonic day 18
(E18) rat embryos according to literature (Sahu et al., 2019). First, the cortex of rat E18 embryos
were dissected, the collected tissue was triturated and the cells isolated, centrifuged and suspended
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 1% L-glutamine and 1% penicillin/streptomycin. Eventually, after making sure all other
cells and their components were removed, the cortical cells were suspended in the growing medium
(2% B-27, 1% L-glutamine and 1% penicillin/streptomycin in NeuroBasal medium) and seeded in
pre-coated wells.
The 96-well plates were coated with 200 μl/well of 10 μg/ml Poly-l-lysine (PLL) and
similarly 500 µl/well of PLL was used with 24-well plates, after which the plates were left to
incubate overnight (ON) at 37°C prior to the cell seeding. Once a week, 30% of the media was
replaced by fresh media but otherwise the cells were kept in the incubator for 8-10 days in vitro.
The cells were cultivated in 96-well plates (60 000 cells/well in 100μl/well of growing medium) for
direct ELISA experiments; or in 24-well plates (250000 cells/well in 500 μl/well of growing
medium) for sandwich ELISA experiments.
For the treatment, the cells that were fixed for direct ELISA received C21 (0.1; 1.0; 10μM)
for 15min. The cells that were lysed for sandwich ELISA experiments received C21 (10μM) either
once for 15min followed by a non-therapeutic treatment of BDNF (0.1ng/ml) for 15min; or C21
once a day for three consecutive days, similarly treated with BDNF 2h after the third treatment of
C21. The same concentrations were used for prolonged treatments.
As soon as the drug treatments were conducted, the cells were washed with ice-cold PBS to
get rid of the remaining substances, and either fixed or lysed depending on the experiment in
question. Every time the plate was incubated for any means, it was kept on a rocking platform to
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maintain stable conditions throughout the samples. For direct ELISA, the cells were fixed by
leaving them in 75μl/well of 4% paraformaldehyde (PFA) for 20min at room temperature (RT),
followed by blocking. On the other hand, the lysing for sandwich ELISA was carried out by
exposing the cells to fresh NP+ lysis buffer (3M Tris-HCl, 5M NaCl, 0.5M NaF, 1% Nonidet-40,
100mM Na3VO4, 10% glycerol in MilliQ-water, supplemented with phosphatase inhibitors
(Sigma-Aldrich, #P0044) and protease inhibitors (Sigma-Aldrich, #P2714)) for 30min at +4°C.
When the lysing was finished, the samples were immediately added to the blocked wells for next
steps of sandwich ELISA.
4.1.3 Direct ELISA
Direct ELISA was used to investigate whether C21 is able to increase the amount of surface TRKB
(sTRKB) similar to previous studies (Zheng et al., 2008; Fred et al., 2019). At first, the already
fixed and collected samples were carefully washed by incubating them in PBS for 5min at RT for
three consecutive washings, after which 200 μl/well of blocking buffer (5% nonfat dry milk and 5%
of bovine serum albumin (BSA) in PBS) was added in the samples for 1h at RT. To investigate the
amount of TRKB, the primary antibody (AB) that specifically targets this receptor (R&D;
#AF1494; 1:500) was dissolved in the blocking buffer, the wells were filled with 100 μl/well of the
solution, and the plate was then sealed and incubated ON at +4°C.
On the second day, the plate was washed with PBS and the secondary, HRP-conjugated AB
targeting goat immunoglobulin G (IgG, Invitrogen; #61-1620; 1:5000) was dissolved in the
blocking buffer and 100 μl/well of the final solution was applied to the wells for 1h at RT. Next the
plate went through four, similar consecutive washings in PBS at RT, changing the liquid between
the washes that each took 10min from start to finish. At the end of the experiment, the wells of the
plate were filled with 100 μl/well of enhanced chemiluminescence (ECL, 1:1) solution that was
used to quantify the amount of sTRKB by Varioskan Flash, Thermo Scientific. The amount of
sTRKB was gained when the background (wells without cells) was discounted from the
chemiluminescence emitted from the samples. The untreated controls were compared to C21-treated
samples, and the final results were displayed percentually.
4.1.4 Sandwich ELISA
The effect of C21 on BDNF-induced phosphorylation of TRKB (TRKB:pY) was studied with
sandwich ELISA by the already established instructions (Fred et al., 2019). In the beginning of the
experiment, the primary AB targeting TRKB (R&D; #AF1494; 1:1000) was dissolved in a
carbonate buffer (57.4mM NaHCO3, 42.6mM Na2CO3, pH = 9.8), and a prepared solution was
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used for coating the 96-well plate, 100 μl/well respectively. The plate was sealed and incubated ON
at +4°C. On the second day, the plate was prepared for drug-treated samples by incubating in 200
μl/well of blocking buffer (2% BSA in PBS with 0.1% Tween 20 (PBS-T)) for 2h at RT. When the
drug treatments and the sample collection were finished, the plate was returned to the +4°C room
ON.
On the third day, the plate was washed with PBS-T. To measure the phosphorylation in the
samples, they were exposed to 100 μl/well of biotinylated secondary AB that targets tyrosine
phosphorylated proteins (BioRad; #MCA2472B; 1:2000) dissolved in the blocking buffer at +4°C
ON. On day four, the plate was washed and the previous AB solution was replaced with 100 μl/well
of tertiary HRP-conjugated streptavidin solution (Thermo Scientific Pierce; HRP-streptavidin;
#21126; 1:5000), respectively prepared in the blocking buffer, 2h at RT. One last washing was
conducted and 100 μl/well of ECL (1:1) was applied to quantify TRKB:pY in the samples by
Varioskan Flash, Thermo Scientific. The results were processed and interpreted in a similar manner
as in the direct ELISA.
4.2 In vivo experiments
4.2.1 Drug treatments in vivo
Sterile saline was used as a vehicle for C21 (0.3 mg/kg; 0.009 μg/day) (Namsolleck et al., 2013)
and administered during isoflurane-induced (2%, Vetflurane®, Virbac) anesthesia.
4.2.2 Mouse strains
In order to investigate if BDNF is crucially involved in the effect of C21, a strain of Bdnf
haploinsufficient (BDNF heterozygous, BDNF.het) mice was used. These animals exhibit
significantly attenuated synthesis of BDNF in several brain regions (Ibarguen-Vargas et al., 2009;
Hill and van den Buuse, 2011).
4.2.3 Animals
In this study, 34 female mice (C57BL/6J-000664 background) were exposed to contextual fear
conditioning (20 wild types (WT) and 14 BDNF.het) and 12 for EPM (all WT). All animals were
genotyped upon weaning, and were at the 16-18 week old age during the experiments.
All animals were maintained in the Laboratory Animal Center in the Viikki Campus of
University of Helsinki, group-housed (4-5 animals per cage) in type ll individually ventilated cages
(552 cm2 floor area, Tecniplast, Italy). During all times outside the drug treatments and
experimental procedures, the animals are provided with a constant supply of food and water. As the
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final step of each behavioral experiment all animals are appropriately euthanized with CO2,
followed by cervical dislocation. All procedures used in this study were approved by the
Experimental Animal Ethical Committee of Southern Finland (ESAVI/38503/2019).
4.2.4 Administration of C21
The adoption of AGTR2 agonists, such as C21, into clinical use has been limited as they generally
do not penetrate blood brain barrier (BBB) and are therefore unable to access CNS at therapeutic
levels (Shraim et al., 2011; Bennion et al., 2018). Similarly, C21 has trouble penetrating the BBB
and generally does not reach the CNS at therapeutic levels when administered intraperitoneally or
intravenously (Shraim et al., 2011; Bennion et al., 2018).
Fortunately, a solution has been found in administering these BBB-impermeable substances through
the nose-to-brain route (N2B) (Dhuria et al., 2010; Bennion et al., 2018; Hanson et al., 2013), where
any desired substance is directly administered in the nasal cavity of the animal where it is absorbed
and delivered to the CNS via the olfactory nerves, trigeminal nerves and perivascular transport
(Dhuria et al., 2010). Another advantage of this administration route lies in its specificity due to
which it is possible to use lower doses whereas the systemic exposure to the administered substance
remains low (Dhuria et al., 2010). In fact, this administration route has been successfully used to
deliver C21 to the CNS, followed by therapeutic, neuroprotective effects (Bennion et al., 2018).
Regarding this study, N2B administration of drugs was carried out by following the protocol
found in the literature (Hanson et al., 2013) with slight adjustments. Even though the administration
could have been executed without anesthesia, the decision to use a mild, isoflurane-induced
anesthesia was made to ensure that the animals were easily handled and less stressed by the
procedure. At first, the group-caged mice were moved to the transparent chamber where they were
exposed to 2% of isoflurane for 4min. Before administration, the level of anesthesia was tested by
pinching the paw gently to investigate paw reflexes. The animal was held vertically, and the head
was tilted, and then the N2B drug administration was carried out with the help of a micropipette
attached with a long and thin tip suitable for delivery. Finally, 20μl of the assigned treatment was
administered through N2B depending on the treatment group of the animal (WT/vehicle, WT/C21,
BDNF.het/vehicle, BDNF.het/C21). The other nostril was used for the drug treatment the following
day. The drug treatments were continued for three consecutive days, followed by either contextual
fear conditioning or EPM 2h after the treatments were completed.
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4.2.5 Treatment groups
In the contextual fear conditioning, there were four different groups: WT/vehicle (N = 8), WT/C21
(N = 12), BDNF.het/vehicle (N = 6) and BDNF.het/C21 (N = 8). In the EPM, there were only two
treatment groups: WT/vehicle (N = 6) and WT/C21 (N=6).
4.2.6 Contextual fear conditioning
The contextual fear conditioning was used to investigate how C21 affects the response to stress
(Michels et al., 2018). During the experiment, the freezing time (s), the mean velocity (cm/s) and
travelled distance (cm) were recorded by TSE Instruments, Germany. Following the drug treatments
(Figure 1A), one animal at the time was exposed to the Context A (23x23x35cm, chamber with
clear acrylic walls and metal grid floor, Figure 1B) where three electric foot shocks (0.6mA/2s)
were delivered in 10min. Shocks were assumed to induce fear conditioning, associated with this
specific context. The mean velocity of each animal was measured to confirm that all animals
actually received and responded to the shocks. Travelled distance was measured during the first
2min before any shocks were delivered to estimate the locomotion and activity of each animal.
On the following day, the chamber was replaced by an unfamiliar Context B (23x23x35cm,
chamber with black acrylic walls and black acrylic floor, Figure 1C), and the freezing response was
monitored in the absence of shocks to investigate if the conditioning induced fear in general.
Animals were exposed to Context B for 5min. On the following day animals were re-exposed to the
familiar Context A to investigate if the familiar environment by itself would induce freezing in the
5min (Figure 1D). In the end, the freezing times between the conditioning session and re-exposing
to familiar Context A were compared with each other to investigate how different groups responded
to the context-induced stress.
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Figure 1. Experimental design of contextual fear conditioning. A) The animals were treated daily with desired drug
treatments (vehicle, C21) on three consecutive days. B) When treatments were finished, the animals were left alone for
2h before Context A was used to induce contextual fear conditioning by electric foot shocks, three shocks in 10min. C)
In the unfamiliar Context B, animals were investigated for generalized fear for 5min. D) Finally the mice were
re-exposed to the familiar Context A to measure context-induced freezing in 5min.
4.2.7 Elevated plus-maze
In the present study, the EPM was used to investigate the fear and anxiety in an ethological setting
without conditioning after C21 treatment. The EPM was adjusted following the general protocol
found in the literature (Walf and Frye, 2007). The EPM is a plus-shaped apparatus (Figure 2A) with
two OAs (30 x 5cm) and EAs (30 x 5cm) that are surrounded by the protective walls (20cm). The
whole apparatus was placed 40cm from the floor, creating an ethological experience of fear.
In the beginning of the experiment, one animal at the time was placed in the middle area (5
x 5cm) of the EPM (Figure 2B). During the whole experiment (5min), the animal was recorded by
Ethovision XT 13, Noldus, Netherlands, and the movement of the animal was measured as travelled
distance, presenting the overall activity of the animal. The number of entries to the EAs and the
percentage of entries to the OAs of the EPM were measured as enclosed arm entries (EAE) and
open arm entries (%OAE). Additionally, the percentage of time animals spent in the OAs of the
EPM was counted (%OAT). If the drug induced an anxiolytic effect, the OAE and OAT were
assumed to increase, while any locomotor effect of the treatment should reflect on EAE and the
travelled distance.
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Figure 2. Experimental design of EPM. A) Picture of the EPM apparatus from the side. EPM is placed 40cm upon the
floor, inducing unconditioned fear. B) EPM has two open arms (OAs) and enclosed arms (EAs) of similar size. The
OAs of the EPM are also part of the ethological nature of this method as they create approach-avoidance conflict. The
apparatus used in the present study was made of acrylic with opaque floors and transparent walls.
4.3. In silico experiments
To further investigate what cells might be involved in the effect of C21, we wanted to investigate
the expression of AGTR2. The data from Allen Mouse Brain Atlas was used to mine information of
different cell subtypes that might express this receptor in the brain (Lein et al., 2007; Morris et al.,
2010). Using the genome browser tool for the mouse ribonucleic acid (RNA) sequencing data
(https://celltypes.brain-map.org/rnaseq/mouse/v1-alm), a heatmap was created for the expression of
Agtr2 in different classes and subclasses of cells in the visual and motor cortices.
Cell Classes: GABAergic, glutamatergic, non-neuronal, endothelial; Subclasses:
Lysosomal Associated Membrane Protein Family Member 5 (Lamp5), Synuclein-gamma (Sncg),
Serpin Family F Member 1 (Serpinf1), Vasoactive intestinal polypeptide (Vip), Somatostatin (Sst),
Parvalbumin (Pvalb), Layer 2/3 intratelencephalic (IT), Layer 4, Layer 5 IT, Layer 6 IT, Layer 5
principal neurons, Neuropil (NP), Layer 6 corticothalamic, Layer 6b, Meis homeobox 2 (Meis2),
Calcitonin receptor, Astrocyte, Oligodendrocyte, Vascular and leptomeningeal cell (VLMC),
Periostin, Structural Maintenance of Chromosomes (SMC), Endothelial, Macrophage.
4.4. Statistical Analysis
Kruskas-Wallis test and two-way ANOVA [Factors: C21 effect and BDNF effect] were used as the
main analysis methods for the analysis of in vitro experiments. Kruskal-Wallis test indicated a
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significant difference in the treatment groups that was further investigated with Dunn’s post hoc
test. Similarly, two-way ANOVA was accompanied by Fisher’s Least Significant Difference (LSD).
Two-way ANOVA, a multiple analysis of variance (MANOVA) and the two-tailed unpaired
t-test were used to analyse in vivo experiments. The contextual fear conditioning was mostly
analysed with the two-way ANOVA but in order to allow an overall analysis of the interaction
between treatment and genotype along the fear conditioning session (freezing in the last 2min of
conditioning, in the unfamiliar Context B and in the familiar Context A), all groups (WT/vehicle;
WT/C1; BDNF.het/vehicle; BDNF.het/C21) were analysed with MANOVA. MANOVA analysis
was carried out with the trials as repeated measures, genotype and treatment as factors, and the
travelled distance prior to the shock-delivery as covariant, and this test was used to analyze the
changes in mean velocity during the conditioning session as well. The locomotor activity preceding
the delivery of shocks was analysed by two-way ANOVA [Factors: C21 effect and Genotype
effect]. All ANOVA and MANOVA analyses were additionally analysed with Fisher’s LSD. In
contrast to contextual fear conditioning, all analyses of EPM were carried out with two-tailed
unpaired t-test. The statistical significance was reached if the P value was below 0.05. The
effect-sizes for both in vitro and in vivo treatments were determined by calculating Glass’ delta
values according to literature (Hedges and Olkin, 2014), and data was stored in FigShare under a
CC-BY-SA license, DOI:10.6084/m9.figshare.12593396.
5 Results
5.1 C21 elevates the amount of sTRKB in vitro
Exposing cortical cells to different concentrations of C21 (0.1, 1.0, 10μM) for 15min led to the
elevated amount of sTRKB [Kruskal-Wallis (3): 58.50, P < 0.0001; Figure 3A]. The concentration
of sTRKB was increased in all groups treated with C21 (Dunn’s, P < 0.05), from which the 10μM
concentration appeared as the most effective one despite the larger distribution of the values [Glass’
delta values: 0.1μM = 1.862; 1.0μM = 2.218; 10μM = 18.188]. Therefore, the 10μM concentration
was used in the following in vitro experiments.
Since C21 appeared to have an impact on sTRKB, the effect of C21 on BDNF:TRKB
signaling was studied next. As expected, a non-therapeutic treatment of BDNF (0.1 ng/ml) for
15min could not activate TRKB on its own, and similarly C21 (10μM) for 15min was also
ineffective (Figure 3B). Interestingly, combining these treatments together successfully enhanced
the effect of BDNF, inducing the activation of TRKB with a significant interaction between the
treatments [Two-way ANOVA: C21 effect: F (1, 33) = 3.755, P = 0.0613; BDNF effect: F (1, 33) =
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2.727, P = 0.1082; Interaction: F (1, 33) = 7.144, P = 0.0116]. Furthermore, when C21 treatment
(10μM) was prolonged to three consecutive days, TRKB activation was significant in the
C21-treated group (Figure 3C). In addition to this, a non-therapeutic treatment of BDNF (0.1 ng/ml)
for 15min still elevated TRKB activation after pretreatment of C21 [Two-way ANOVA: C21 effect:
F (1, 44) = 423.5, P < 0.0001; BDNF effect: F (1, 44) = 0.5861, P = 0.4480; Interaction: F (1, 44) =
10.22, P = 0.0026].
Figure 3. C21 effect on BDNF:TRKB signaling studied with ELISA. A) Exposing cells to C21 (0.1; 1.0; 10μM) for
15min significantly elevated the amount of sTRKB, 10μM concentration standing out as the most effective from the
rest. B) Combination of C21 (10μM) for 15min and a non-therapeutic treatment of BDNF (0.1 ng/ml) for 15min
activated TRKB. C) The effect on TRKB activation was further elevated in all cells predisposed to C21 (10μM) for
three consecutive days. The cells that were additionally treated with BDNF (0.1 ng/ml) for 15min showed the strongest
effect. Bars: mean/SEM of percentage compared to ctrl group of surface (sTRKB) and phosphorylated (TRKB:pY)
TRKB. * p < 0.05 compared to ctrl.
5.2 C21 has an anti-stress effect in the contextual fear conditioning
The contextual fear conditioning was carried out following the N2B administered drug treatments
(Figure 4), with four treatment groups: WT/vehicle, WT/C21, BDNF.het/vehicle and BDNF/C21.
During the contextual fear conditioning that took place in Context A, three distinct electric shocks
were delivered to all animals, which can be observed as the three peaks in mean velocity on each
graph (Figures 5A - 5D). For clarity, the data for each group was plotted separately. The overall
analysis of mean velocity during the conditioning session indicates no interaction between
treatment, genotype and time [MANOVA: Interaction: F (14, 420) = 1.556, P = 0.089]. The between
factors analysis indicates a significant interaction but no significant effect of treatment or genotype
alone [MANOVA: C21 effect: F (1, 30) = 1.778, P = 0.192; Genotype effect: F (1, 30) = 0.0005, P =
0.981; Interaction: F (1, 30) = 7.056, P = 0.013].
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Figure 4. Timeline of contextual fear conditioning. Drug treatments: Before the actual experiment took place, all
treatment groups (WT/vehicle, WT/C21, BDNF.het/vehicle, BDNF.het/C21) were treated with their assigned treatments
for three consecutive days through a nose-to-brain route (N2B). The contextual fear conditioning consisted of three
different phases that were carried out on different days as the timeline demonstrates: Context A: Conditioning; Context
B: Unfamiliar and Context A: Familiar.
All WT mice showed similar levels of mean velocity regardless of their assigned treatment
(Figure 5A - 5B). The first shock produced a weaker response in the BDNF.het/C21 group, which
can be observed as a lower first peak of the mean velocity curve compared to the vehicle-treated
animals of the same genotype (Fisher's LSD, P < 0.0001, Figure 4D). Despite that, all BDNF.het
mice responded similarly to the following two shocks, indicating that this could be normal variation
derived from the new context. As a conclusion, neither the treatment nor genotype affected the
starting condition of the animals.
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Figure 5. All animals received three shocks during the contextual fear conditioning. A-B) The graphs indicate how
the mean velocity (cm/s) of WT mice increased in three different timepoints when the electric shocks were delivered
during the fear conditioning (10min). As a conclusion, all mice received the shocks and there was no difference between
the treatment groups (vehicle, C21). C-D) Similar to WT animals, both graphs indicate how three distinct electric
shocks were delivered to BDNF.het mice in different timepoints during the fear conditioning (10min). BDNF.het/C21
mice had a weaker response to the first shock compared to the BDNF.het/vehicle mice. Graphs: mean/SEM of mean
velocity (cm/s) along the conditioning session. *p < 0.05 compared to all other groups at the same time point.
The travelled distance, measured in the first 2min of the conditioning session (before the
shocks), did not indicate any significant difference in the locomotion between WT and BDNF.het
animals [Two-way ANOVA: C21 effect: F (1, 30) = 1.078, P = 0.3074; Genotype effect: F (1, 30) =
1.178, P = 0.2864; Interaction: F (1, 30) = 2.629, P = 0.1154; Figure 6A]. The travelled distance as
covariant, the overall analysis of the freezing during the last 2min of the conditioning session, in the
Context B and in the Context A, reveals a significant interaction between treatment, genotype and
sessions [Two-way ANOVA, repeated measures: Interaction: F (2, 58) = 3.631, P = 0.033].
Therefore, in addition to overall analysis, each session was analysed separately. During the last
2min of the conditioning session, there was no difference in freezing between the groups regardless
of their treatment or genotype [Two-way ANOVA: C21 effect: F (1, 30) = 0.4826, P = 0.4926;
Genotype effect: F (1, 30) = 0.6875, P = 0.4136; Interaction: F (1, 30) = 0.1451, P = 0.7059; Figure
6B].
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When the context was changed to the unfamiliar Context B, similar results were discovered
in the terms of freezing as there was no interaction between the factors [Two-way ANOVA: C21
effect: F (1, 30) = 0.1342, P = 0.7167; Interaction: F (1, 30) = 0.03355, P = 0.8559; Figure 6C].
However, BDNF.het animals froze significantly more compared to WT animals, regardless of their
treatment group [Two-way ANOVA: Genotype effect: F (1, 30) = 21.28, P < 0.0001]. Despite this,
the results did not indicate that the animals would have been suffering from generalized fear after
the conditioning session.
When animals were re-exposed to the familiar Context A, where they had received electric
shocks during the fear conditioning, there was a significant interaction between the treatment and
genotype [Two-way ANOVA: C21 effect: F (1, 30) = 18.34, P = 0.0002; Genotype effect: F (1, 30)
= 55.60, P < 0.0001; Interaction: F (1, 30) = 5.012, P = 0.0327; Figure 6D]. Interestingly, the
C21-treated WT mice froze significantly less compared to the WT/vehicle group (Fisher’s LSD, p <
0.05; Glass’ delta value = 2.847). However, BDNF.het/C21 animals did not benefit from the
treatment (Glass’ delta value = 0.613).
Figure 6. C21 protects WT mice from stress and this effect disappears in BDNF.het mice in the contextual fear
conditioning. A) All animals regardless of their treatment group (WT/vehicle, WT/C21, BDNF.het/vehicle,
BDNF.het/C21) showed similar amounts of activity during the first 2min of the contextual fear conditioning in the
Context A (before the shocks). B) Furthermore, all animals froze as much during the last 2min in the Context A. C) In
the unfamiliar Context B, animals did not freeze more, indicating that the conditioning did not induce generalized fear.
Both BDNF.het groups froze more compared to the WT animals. D) In the familiar Context A, WT/C21 mice froze
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significantly less. In contrast, BDNF.het animals showed overall more freezing and C21 treatment lacked effect in this
genotype. Bars: mean/SEM of the freezing time (s). *p < 0.05 compared to the WT/vehicle group.
5.3 C21 did not relieve anxiety in the EPM
The anxiety-like behavior of animals was investigated with EPM. This was executed with another
group of WT mice, specifically with WT/vehicle and WT/C21. Interestingly, the travelled distance
was similar between the WT/vehicle and WT/C21 groups [Unpaired t-test: t = 0.03208; df = 10; P =
0,9750; Glass’ delta value = 0.014; Figure 7A], and there was no difference in the EAE either
[Unpaired t-test: t = 1.351, df = 10; P = 0,2064; Glass’ delta value = 0.632; Figure 7B]. Similarly,
both %OAE [Unpaired t-test: t = 1.097, df = 10; P = 0,2984; Glass’ delta value = 0.592; Figure 7C]
and %OAT [Unpaired t-test: t = 0.9135, df = 10, P = 0,3825; Glass’ delta value = 0.525; Figure 7D]
were not affected by the administration of C21.
Figure 7. C21-treated WT mice indicated as much anxiety as the vehicle-treated animals in the EPM. A) There
was no difference between the activity of WT/vehicle or WT/C21 mice. The activity was measured as travelled distance
(cm) in 5min. B) WT/vehicle mice showed as much willingness to enter the enclosed arms of the plus-maze as the
WT/C21 mice, measured as entries in the enclosed arms (EAE). C) Likewise, the percentage of open arm entries
(%OAE) was similar between the WT/vehicle and WT/C21 mice, indicating that C21 did not induce any anxiolytic
effect in mice. D) Supporting this, the open arm time (%OAT) of the plus-maze was similar in the WT/C21 group. Bars:
mean/SEM.
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5.4 AGTR2 is expressed in the GABAergic interneurons
In order to have insights about what cells express AGTR2, the levels of this protein were mined in
silico from the Allen Institute database. Since the AGTR2 expression was only significant in the
GABAergic cells (top row), only this class was plotted in the heatmap (Figure 8). The heatmap
shows that compared to other cell subclasses, AGTR2 expression seems to overlap with Lamp5 and
Sst expressing cells, from which the expression is stronger in the Sst subtype. Compared to Pvalb
positive (PV+) interneurons, another subclass of GABAergic interneurons, the expression of
AGTR2 in the Sst positive (SST+) interneurons is clearly stronger. These results indicate that
AGTR2 are mostly located in the subclass of GABAergic, in Lamp5 positive (Lamp5+) and in
SST+ interneurons.
Figure 8. Heatmap of AGTR2 expression in different GABAergic neuronal subtypes. Cell class: GABAergic = top
row. Cell subclasses: Lamp5, Sncg, Serpinf1, Vip, Sst, Pvalb. The expression of AGTR2, presented as vertical lines in a
logarithmic scale. The amount of expression is presented as a spectrum of colors from blue to red, blue being smaller
and red being stronger. Some of the subclasses that seemed to express more AGTR2 were observed in more detail. The
heatmap shows that AGTR2 expression is linked to the GABAergic subclass of SST+ interneurons. Allen Mouse Brain
Atlas (Lein et al., 2007; Morris et al., 2010) was used for data mining.
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6 Discussion
This study shows that AGTR2 stimulation by different concentrations of C21 for 15min results in
elevated amounts of sTRKB in cortical cell cultures. A similar effect has been observed with ANG
through an AGTR2-dependent mechanism, where heterodimerization of TRKB:AGTR2 was also
present (Diniz et al., 2018). Even though TRKB is located in the cell membrane, it is mostly found
inside vesicles within the cells where it is being driven into the cell membrane following
BDNF:TRKB signaling to allow more interaction (Haapasalo et al., 2002). Furthermore, ADs have
been shown to compromise the clathrin-dependent endocytosis that keeps the TRKB internalized,
and thus increase the localization of TRKB in the surface, which has been suggested to play a
crucial role in their mechanism of action (Fred et al., 2019). Results of the present study suggest
that the therapeutic effect of C21 might work through a similar mechanism, despite failing to
activate TRKB after acute administration. Interestingly, the prolonged treatment of C21 achieved
this effect. This could be a consequence of the elevated amount of sTRKB that might enhance
BDNF:TRKB signaling after a prolonged AGTR2 stimulation.
Furthermore, AGTR2 stimulation by C21 and an additional treatment of non-therapeutic
BDNF both acutely and after a prolonged trial were followed by TRKB activation. As known,
TRKB plays a crucial role in the mechanism of action of ADs (Castrén and Antila, 2017) and thus,
allowing more TRKB to access the cell surface facilitates its interaction with BDNF and
consequently BDNF:TRKB signaling. Hence, the elevated amount of sTRKB that follows the
AGTR2 stimulation seems to be behind the facilitation of BDNF-induced activation of this receptor.
Furthermore, according to our recent study the stabilization of the signaling-competent
conformation of TRKB is behind the mechanism of several different ADs (Casarotto et al., 2021).
According to the results of the contextual fear conditioning AGTR2 stimulation protects
from consequences of stress. The animals pretreated with C21 exhibited lower freezing when
re-exposed to the familiar context that had been associated with the fear-inducing stimulus during
conditioning. Moreover, this therapeutic effect on stress was completely absent in BDNF.het mice.
Similarly, the BDNF.het animals were resistant to the antidepressant-like effect that relieved the
consequences of stress in WT animals in the unpredictable chronic mild stress (UCMS) paradigm
(Ibarguen-Vargas et al., 2009), and these animals also resisted the effects of AGTR1 antagonist
losartan in the FST (Diniz et al., 2018). In the present study BDNF was also necessary for elevated
activation of TRKB in vitro, and thus the lack of effect in vivo points to the same conclusion that
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the therapeutic effects of C21 are dependent on BDNF and possibly a consequence of elevated
sTRKB.
Interestingly, the results of EPM indicate that C21 does not work as an anxiolytic, which is
surprising, since deficiency of AGTR2 has been associated with increased anxiety (Okuyama et al.,
1999). Since pretreatment with C21 was able to protect from the consequences of stress in the
contextual fear conditioning, this could indicate an important confounding effect at the conditioning
session and responsiveness to stress. It is widely accepted that glutamate is a crucial regulator of our
stress response as it indirectly elevates the amount of glucocorticoids in response to acute and
prolonged stress through the stimulation of hypothalamus-pituitary-adrenal (HPA) axis (Evanson
and Herman, 2015). When paraventricular nucleus (PVN) of the hypothalamus is stimulated by
glutamate, corticotropin-releasing hormone (CRH) secretion is triggered, which leads to
adrenocorticotropic hormone (ACTH) release from anterior pituitary, and finally the production of
glucocorticoids in the adrenals (Evanson and Herman, 2015). Moreover, the synthesis of
glucocorticoid receptors located in the prefrontal cortex (PFC) has been shown to diminish in
response to chronic stress (Chiba et al., 2012). Of importance, several AGTR1 antagonists have
been shown to prevent the stress-induced elevation of glucocorticoids (Pavel et al., 2008;
Wincewicz et al., 2016; Campos et al., 2020). Furthermore, exposing cortical cells to glutamate for
24h shifts the ratio between AGTR1 and AGTR2 synthesis towards AGTR1, preventing ANG from
activating TRKB through AGTR2 without previous AGTR1 blockade by losartan (Diniz et al.,
2018). Stress has been shown to decrease BDNF synthesis in the mPFC, which can be prevented by
blocking AGTR1 with telmisartan (Wincewicz et al., 2016). Stress is also followed by reduced
synthesis of corticotropin-releasing factor 1 (CRF1) in the cortex, again prevented by an AGTR1
blockade (Saavedra et al., 2006; Pavel et al., 2008).
Similar to present study with C21, AGTR1 antagonists candesartan and telmisartan did not
induce any anxiolytic effect in the EPM whereas they still alleviated the stress-induced deficits on
the cognitive function (Braszko et al., 2013; Wincewicz and Braszko, 2014). However, there are
some contradictory studies in literature where different AGTR1 antagonist treatments are able to
alleviate anxiety in the EPM (Saavedra et al., 2006; Pavel et al., 2008; Wincewicz et al., 2016). For
example, AGTR1 blockade by losartan was followed by an anxiolytic-like effect in the EPM even
though this treatment was not able to attenuate the elevated AGTR1 synthesis in the HC of these
animals (Campos et al., 2020). Taken together, several pieces of evidence suggest that the blockade
of AGTR1 seems to indirectly enhance AGTR2 function, which in turn engages BDNF:TRKB
system to exert its effects (Diniz et al., 2018). This indirect activation of AGTR2 could explain how
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these compounds attenuate the stress-induced increase in the glutamate level, glucocorticoids and
increased AGTR1 activity.
On the other hand, the AGTR2-mediated effect could also be dependent on the cell type that
expresses these receptors and the exact location of these cells in the brain, especially involving the
fear-regulating circuits. Direct infusion of losartan into the HC and mPFC of rats induced an
antidepressant-like effect in the FST, indicating a significant role of these two brain regions in the
therapeutic effects of AGTR2 stimulation (Diniz et al., 2018). However, when this effect was
investigated in more detail by inducing the AGTR2 blockade in both structures, the effect of
systemic losartan was only compromised by previous AGTR2 blockade in the mPFC (Diniz et al.,
2018). As stated previously, the mPFC is crucially involved in the regulation of both conditioned
and unconditioned fear and, in fact, AGTR2 is expressed in neurons located in the mPFC, with low
expression in the hippocampus (de Kloet et al., 2016). Furthermore, some of these neurons are
located in the amygdala and BNST, the latter of which were further speculated to send GABAergic
projections to the PVN that by itself did not express AGTR2 (de Kloet et al., 2016).
Using the Allen Mouse Brain Atlas to mine for information about the neuronal subtypes
expressing AGTR2, we observed that AGTR2 expression significantly overlaps with GABAergic
SST+ interneurons. In contrast, the AGTR2 expression in the PV+ interneurons is almost
non-existent. This and the role of SST+ interneuron populations in the mPFC, amygdala and BNST
suggests that SST+ interneurons located in these brain regions might be responsible for the
therapeutic effects of C21. MDD has been linked to a significant attenuation of the SST synthesis in
the PFC (Sibille et al., 2011). In addition, SST seems to possess mood recovering effects as a direct
infusion into the cerebrospinal fluid has been associated with attenuated anxiety- and
depressive-like behavior in rats (Engin et al., 2008). Furthermore, it has been demonstrated that a
chronic exposure to stress induces plastical changes in the mPFC that results in the elevated
synthesis of GABA A α1 (GABAAα1) receptor and morphological changes such as dendritic
hypertrophy especially in the GABAergic SST+ interneurons (Gilabert-Juan et al., 2013).
After the exposure to chronic stress, the synthesis of SST has been shown to diminish in the
mPFC located SST+ interneurons in mice (Jefferson et al., 2020). However, the disinhibition of
SST+ interneurons protects from this deficit, and additionally alleviates other consequences of
stress in male mice only (Jefferson et al., 2020). This sex-specific finding also supports the results
of a previous clinical study, where the MDD was linked with attenuated synthesis of subgenual
anterior cingulate cortex (sACC)-located SST especially in females (Tripp et al., 2011). One of the
limitations of the present study is that the effects of C21 were only investigated in the female
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animals. Therefore, possible sex-specific effects remain unknown. Even though the animals
responded to the treatment in the contextual fear conditioning, a sex-specific effect might partly
explain the results of EPM. However, this remains only as a speculation until studied further.
Disinhibition of forebrain-located SST+ interneurons elevates their inhibitory effect on
HC-located principal neurons, which is followed by behavioral improvement of mice in the
different paradigms measuring stress and anxiety (Fuchs et al., 2017). Similarly, disinhibition of
amygdala located SST+ interneurons and the following attenuation in the activity of principal
neurons seem to compromise fear conditioning (Wolff et al., 2014). This study indicated that the
conditioned fear is a consequence of principal neuron disinhibition, which is linked to the elevated
activity of PV+ interneurons that reduce the inhibitory signaling of SST+ interneurons (Wolff et al.,
2014). Furthermore, the unconditioned fear was associated with attenuated activity of both SST+
and PV+ interneurons, the latter of which was responsible for observed disinhibition of principal
neurons (Wolff et al., 2014).
These findings are interesting, especially considering the results of the present study where
the therapeutic effects of C21 were only present in the contextual fear conditioning but not in the
EPM. As AGTR2 is expressed in the SST+ interneurons, the AGTR2 stimulation by C21 might be
able to recruit these interneurons to enhance their GABAergic signaling on principal neurons in
PFC and amygdala, and thereby attenuate conditioned fear. Even though the activity of PV+
interneurons seems to regulate the activity of SST+ interneurons, C21-induced AGTR2 activity in
SST+ interneurons might be able to oppose their inhibitory effect. Furthermore, the lack of effect in
the EPM could be explained by the PV+ interneurons that at the same time seem to regulate
unconditioned fear and do not express AGTR2. This would also support the idea that the
conditioning session and exposure to stress play a crucial role in the therapeutic effect of C21,
suggesting that C21 is able to protect from the conditioned fear specifically.
In contrast to other studies, the mPFC-located SST+ interneurons have been suggested to
regulate conditioned fear and indicate that inhibiting their GABAergic function reduces the
consequences of conditioned fear (Xu et al., 2019; Cummings and Clem, 2020). According to these
studies, the mPFC-located SST+ interneurons inhibit the activity of PV+ interneurons, thus
reducing their GABAergic signaling to their target neurons, which indirectly leads to disinhibition
of the principal neurons (Xu et al., 2019; Cummings and Clem, 2020). In line with other studies,
the activity of mPFC and disinhibition of principal neurons were crucially involved in the
mechanism that induced conditioned fear according to these studies (Xu et al., 2019; Cummings
and Clem, 2020). This raises the question whether SST+ interneurons act differently depending on
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their location in the brain. Since the studies conducted in the forebrain and mPFC resulted in
entirely opposite results, the SST+ and PV+ interneurons should be studied more to confirm how
they are involved in the regulation of fear.
Furthermore, it is rather likely that different brain regions are also involved in the
mechanism of action of C21, especially since AGTR2 expressing cells can be also found from the
BNST. Taking this together with the knowledge of fear circuits, it might be possible that
C21-induced AGTR2 activity in the mPFC and amygdala located SST+ interneurons that could
further signal to BNST and indirectly attenuate the activity of PVN and entire HPA axis. However,
this remains under speculation as long as the exact cell type regulating the effect of C21 remains
unidentified. The future studies should focus on answering this question to widen the current
knowledge of how the therapeutic effects of C21 are generated. Since C21 can be easily
administered through N2B, this might make it easier to translate this drug into clinical use for
treating mood disorders in the future.
7 Conclusions
According to both in vitro and in vivo results of this study the BDNF:TRKB signaling plays a
crucial role in the mechanism of action of C21. Stimulation of AGTR2 by C21 allows TRKB to
access the cell surface in larger amounts, followed by enhanced BDNF:TRKB interaction and the
receptor activation. Nevertheless, by itself C21 fails to activate TRKB. Therefore, AGTR2
stimulation induces a facilitatory effect on BDNF.
C21 has stress-protective effects where the AGTR2 stimulation by this compound attenuates
the contextual fear conditioning -induced stress without relieving anxiety in the elevated plus-maze,
thus indicating the dependence of the exposure to stress. The essential role of BDNF in the
therapeutic effect of C21 is apparent as it disappears in the BDNF-deficient animals. The C21 effect
may be linked to the SST+ interneurons in the mPFC but future studies are needed to test this
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